DRKS00000811已完成不适用
AFP – L3% and DCP as screening marker for a hepatocellular carcinoma in patients with cirrhosis of the liver - HCC - Surveillance- Trial
KL Freiburg, Med. Klinik II0 个研究点目标入组 400 人开始时间: 2011年5月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- All
入选标准
- •age between 18 and 80
- •- cirrhosis of the liver confirmed by ultrasound or other imaging techniques (MRI, CT) or biopsy
- •- at the time of enrollment: no HCC- suspected lesion detectable in the liver
排除标准
- •other liver tumors or metastasis or tumor of unknown origin
研究者
相似试验
已完成
不适用
AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the LiverLiver CirrhosisNCT01361061University Hospital Freiburg450
已完成
不适用
AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)Hepatocellular CarcinomaNCT01360255University Hospital Freiburg70
招募中
Unknown
Evaluation of molecular biomarkers for hepatocellular carcinoma (HCC) therapyLiver CirrhosisOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonCancer - LiverLiver CancerHepatocellular CarcinomaACTRN12623000762651A/Prof Adam Testro150
尚未招募
不适用
ew tumor marker for early detection of hepatocellular carcinoma (HCC)Apply to basic benefits in screening people at high risk of liver cell cancer at the national levelPIVKA-IIAFP-L3TCTR20200313001one1,080
已完成
不适用
Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective StudyHepatocellular CarcinomaCirrhosisNCT00629421Kaohsiung Medical University Chung-Ho Memorial Hospital1,200